Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel biologic therapeutic candidates for individuals with life-threatening conditions, primarily focusing on oncology and orphan diseases. Headquartered in La Jolla, California, the company leverages proprietary protein engineering platforms, including single-domain antibody technology, to create optimized and differentiated medicines.

The company's pipeline features two main clinical-stage candidates: ozekibart (INBRX-109) and INBRX-106. Ozekibart is a tetravalent DR5 agonist designed to induce tumor-selective programmed cell death, currently being evaluated for conventional chondrosarcoma, colorectal cancer, and Ewing sarcoma, with a Biologics License Application (BLA) filing for chondrosarcoma anticipated in early Q2 2026. INBRX-106 is a hexavalent OX40 agonist aimed at potent activation of the OX40 costimulatory pathway to enhance antitumor activity, with ongoing clinical trials for various cancers, including first-line head and neck cancer.

Inhibrx Biosciences, Inc. emerged in 2024 as a spin-off from the original Inhibrx, Inc. following Sanofi's acquisition of the INBRX-101 program. The new entity retained the oncology-focused pipeline and operates as an independent public company. Led by CEO and Chairman Mark P. Lappe, the company's market valuation is primarily driven by its clinical data, regulatory advancements, and strategic positioning in the biopharmaceutical landscape.